Commercial genomics inquiry response
Genomics is becoming increasingly popular and accessible owing to the availability of commercial at-home DNA testing kits. However, there are concerns that the commercial genomics industry is largely unchecked.
The inquiry explored the standards required of commercial genomics companies, the ability of genomic tests to provide accurate health results, the potential implications for the NHS and the data protection measures required to ensure the secure storage and sharing of sensitive data.
To read the Sanger Institute’s full response to this inquiry, please click download the PDF below.